AU2003229434A1 - Cancer vaccines and methods of using the same - Google Patents

Cancer vaccines and methods of using the same

Info

Publication number
AU2003229434A1
AU2003229434A1 AU2003229434A AU2003229434A AU2003229434A1 AU 2003229434 A1 AU2003229434 A1 AU 2003229434A1 AU 2003229434 A AU2003229434 A AU 2003229434A AU 2003229434 A AU2003229434 A AU 2003229434A AU 2003229434 A1 AU2003229434 A1 AU 2003229434A1
Authority
AU
Australia
Prior art keywords
methylated
methods
disclosed
immunostimulatory
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003229434A
Other languages
English (en)
Other versions
AU2003229434A8 (en
Inventor
Ghania Chikh
Sandra Klimuk
Sean Semple
Ying K. Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/290,545 external-priority patent/US20030125292A1/en
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of AU2003229434A1 publication Critical patent/AU2003229434A1/en
Publication of AU2003229434A8 publication Critical patent/AU2003229434A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2003229434A 2002-05-10 2003-05-12 Cancer vaccines and methods of using the same Abandoned AU2003229434A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37934302P 2002-05-10 2002-05-10
US60/379,343 2002-05-10
US10/290,545 2002-11-07
US10/290,545 US20030125292A1 (en) 2001-11-07 2002-11-07 Mucoscal vaccine and methods for using the same
US46064603P 2003-04-04 2003-04-04
US60/460,646 2003-04-04
PCT/CA2003/000679 WO2003094828A2 (en) 2002-05-10 2003-05-12 Cancer vaccines and methods of using the same

Publications (2)

Publication Number Publication Date
AU2003229434A1 true AU2003229434A1 (en) 2003-11-11
AU2003229434A8 AU2003229434A8 (en) 2003-11-11

Family

ID=29424457

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003229434A Abandoned AU2003229434A1 (en) 2002-05-10 2003-05-12 Cancer vaccines and methods of using the same
AU2003229433A Ceased AU2003229433B2 (en) 2002-05-10 2003-05-12 Methylated immunostimulatory oligonucleotides and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003229433A Ceased AU2003229433B2 (en) 2002-05-10 2003-05-12 Methylated immunostimulatory oligonucleotides and methods of using the same

Country Status (10)

Country Link
EP (2) EP1503793A2 (https=)
JP (2) JP2005532315A (https=)
CN (1) CN1665531A (https=)
AT (1) ATE411815T1 (https=)
AU (2) AU2003229434A1 (https=)
CA (2) CA2485400A1 (https=)
DE (1) DE60324270D1 (https=)
IL (1) IL165107A0 (https=)
MX (1) MXPA04011127A (https=)
WO (2) WO2003094963A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
JP2012507565A (ja) 2008-10-30 2012-03-29 グオ・ペイシュエン Ｄｎａのシークエンシング及び他の用途のための、膜に組み込まれたウイルスｄｎａパッケージングモータタンパク質コネクタバイオセンサ
EP2484698A4 (en) * 2009-09-28 2014-07-02 Sysmex Corp HYBRIDOMAS FOR THE PRODUCTION OF ANTIBODIES TO METHYLATED DNA AND USE THEREOF
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
CA3183951A1 (en) * 2020-07-14 2022-01-20 Birgitte Rono Apc targeting units for immunotherapy
CN116602920B (zh) * 2023-04-18 2024-03-19 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
FI107974B (fi) * 1999-07-14 2001-10-31 Nokia Networks Oy Menetelmä ja järjestelmä tilastointiin puhelinkeskusjärjestelmässä
EP1212085B1 (en) * 1999-08-27 2007-10-31 INEX Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
EP1441763A2 (en) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid

Also Published As

Publication number Publication date
CA2485400A1 (en) 2003-11-20
WO2003094828A3 (en) 2004-02-05
WO2003094963A2 (en) 2003-11-20
EP1503793A2 (en) 2005-02-09
AU2003229434A8 (en) 2003-11-11
DE60324270D1 (de) 2008-12-04
MXPA04011127A (es) 2005-07-01
JP2005532315A (ja) 2005-10-27
ATE411815T1 (de) 2008-11-15
AU2003229433B2 (en) 2008-04-24
WO2003094828A2 (en) 2003-11-20
WO2003094963A3 (en) 2004-02-12
CN1665531A (zh) 2005-09-07
JP2005530761A (ja) 2005-10-13
EP1506010A2 (en) 2005-02-16
IL165107A0 (en) 2005-12-18
AU2003229433A1 (en) 2003-11-11
EP1506010B1 (en) 2008-10-22
CA2484266A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2003229434A1 (en) Cancer vaccines and methods of using the same
HUP0202639A2 (en) Immunostimulatory nucleic acids
ES2530215T3 (es) Análogos de oligorribonucleótidos inmunoestimulantes que contienen restos de oligofosfato modificados
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
JP2007509983A5 (https=)
OA13278A (en) C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
WO2002044400A3 (en) Compositions and methods for extracting a nucleic acid
WO2000037494A3 (en) Chlamydia trachomatis antigens
WO2002069907A3 (en) Anti-neovasculature preparations for cancer
WO2004016805A3 (en) Immunostimulatory nucleic acids
AU2001239873A1 (en) Adjuvant treatment by in vivo activation of dendritic cells
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
AU2003255621A8 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
IL153200A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
AU2003260426A1 (en) Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
AU2002337697A1 (en) Pine cone extracts and uses thereof
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
ATE464064T1 (de) Aktivierung antigen-spezifischer t-zellen mit virus/antigen-behandelten dendritischen zellen
WO2002010351A3 (de) Autologe bindegewebe, verfahren zu ihrer herstellung und ihre verwendung
WO2001013942A3 (en) Trehalose producing prokaryotic cells as vaccines
WO2006125165A3 (en) Methods and compositions facilitating entry of compounds into cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 527 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME INEX PHARMACEUTICALS CORPORATION , APPLICATION NO. 2003229434, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003